The results of the ADAGIO trial, combined with those of the TEMPO trial and a large body of additional clinical and preclinical data, indicate that the possibility of treatment with rasagiline should be discussed with all patients with early Parkinson disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Disease modification and Neuroprotection in neurodegenerative disorders
Translational Neurodegeneration Open Access 26 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rascol, O., Goetz, C., Koller, W., Poewe, W. & Sampaio, C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359, 1589–1598 (2002).
Olanow, C. W. et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361, 1268–1278 (2009).
Macleod, A. D., Counsell, C. E., Ives, N. & Stowe, R. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD004898. doi:10.1002/14651858.CD004898.pub2 (2005).
Mandel, S., Weinreb, O., Amit, T. & Youdim, M. B. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res. Brain Res. Rev. 48, 379–387 (2005).
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566 (2004).
Hauser, R. A. et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 24, 564–573 (2009).
Marek, K., Jennings, D., Tamagnan, G. & Seibyl, J. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression. Ann. Neurol. 64 (Suppl. 2), S111–S121 (2008).
Leber, P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis. Assoc. Disord. 11 (Suppl. 5), S10–S21 (1997).
D'Agostino, R. B. The delayed-start study design. N. Engl. J. Med. 361, 1304–1306 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. J. Ferreira has acted as a consultant for and received honoraria and research support from Lundbeck and Teva Pharmaceuticals. C. Sampaio declares no competing interests.
Rights and permissions
About this article
Cite this article
Sampaio, C., Ferreira, J. ADAGIO trial hints that rasagiline slows disease progression. Nat Rev Neurol 6, 126–128 (2010). https://doi.org/10.1038/nrneurol.2010.2
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2010.2
This article is cited by
-
Disease modification and Neuroprotection in neurodegenerative disorders
Translational Neurodegeneration (2017)
-
Discordant effects of rasagiline doses in Parkinson disease
Nature Reviews Neurology (2010)